Olaparib (re-assessment: adult patients with advanced (FIGO stages III and IV) epithelial ovarian, fallopian tube or primary peritoneal cancer, homologous recombination deficiency (HRD) positive, maintenance treatment in combination with Bevacizumab)



  • Active Substance: Olaparib
  • Name: Lynparza®
  • Therapeutic area: Ovarian cancer
  • Pharmaceutical company: AstraZeneca GmbH


Time table:

  • Start: 01.11.2022
  • Publication of assessment: 01.02.2023
  • End of public hearing: 22.02.2023
  • Final decision by G-BA: middle of April 2023


Comparative therapy:

  • Continuation of treatment with bevacizumab initiated together with platinum-based first-line chemotherapy